top of page
![Boston_H_color[33632]_edited.png](https://static.wixstatic.com/media/e60c5c_0b72738a80554196840094a8e387c5ed~mv2.png/v1/fill/w_338,h_77,al_c,q_85,usm_0.66_1.00_0.01,enc_auto/Boston_H_color%5B33632%5D_edited.png)
Therapy for Patients with Previously Treated Metastatic Colorectal Cancer (mCRC): Your Patient's Journey
Wed, Aug 05
|Virtual Meeting
INDICATION STIVARGA is indicated for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy.
Registration is Closed
See other events
Time & Location
Aug 05, 2020, 7:00 PM
Virtual Meeting
Guests
About The Event
Presented by:
Denise O'Dea, ANP-BC
URL Link: https:// tallen.adobeconnect.com/bay0000605/ event/registration.html
If you would like to attend, please RSVP at http://www.myspeakerbureau.com/8nIFAF or contact the Bayer Speaker Bureau RegistrationTeam at 866-914-9071 or RSVPBayersb@connectPW.com
bottom of page